This is the first in a series of practice guidelines commissioned by the Infectious Diseases
Society of America through its Practice Guidelines Committee. The purpose of these …

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Bloodstream infections (bacteraemia) account for approximately 25–30% of febrile episodes
in patients with febrile neutropenia (FN). In developed countries, Gram-positive pathogens …

This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and
Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious …

The survival benefit of combination chemotherapy to patients with advanced non-small-cell
carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer …

Purpose: Febrile neutropenia remains a potentially life-threatening complication of anticancer
chemotherapy, but some patients are at low risk for serious medical complications. The …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Three-hundred thirty-two cases of pleural diffuse malignant mesothelioma (DMM) seen at
large centers in Ontario and Quebec from 1965 to 1984 were reviewed retrospectively. …

Thirty-one patients with small-cell lung cancer (SCLC) were treated with VP-16 and cisplatin
as first-line therapy. In the majority of cases an Adriamycin (Adria Laboratories, Columbus, …

… A B S T R A C T … Wiesenfeld M, Marks R, Grill J, et al: A randomized phase II study of
topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel …